An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Camillio PortaPatrizia GiannatempoMimma RizzoGiuseppe LucarelliPasquale DitonnoMichele BattagliaPublished in: Expert opinion on pharmacotherapy (2020)
The positive results of the recently completed OLYMPUS trial suggest the feasibility, activity (59% of complete responses, with just 6 of these complete responders on follow-up who recurred), and safety (68% of patients experiencing mild to moderate urinary adverse events) of UGN-101 instillations into the upper urinary tract. Our expectations are that UGN-101 will soon become a standard of treatment for low-grade UTUC at risk of relapse after either surgery, or nephron-sparing techniques.
Keyphrases
- low grade
- high grade
- urinary tract
- end stage renal disease
- drug delivery
- minimally invasive
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- study protocol
- randomized controlled trial
- peritoneal dialysis
- coronary artery disease
- coronary artery bypass
- replacement therapy
- smoking cessation
- phase ii
- double blind